JG
ATRA icon

Jefferies Group’s Atara Biotherapeutics ATRA Stock Holding History

Jefferies Group’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,800
Closed -$545K – 1644
2022
Q2 		$545K Buy
+2,800
New +$457K ﹤0.01% 962
2020
Q1 		– Sell
-538
Closed -$222K – 2045
2019
Q4 		$222K Sell
538
-18
-3% -$6.21K ﹤0.01% 2202
2019
Q3 		$196K Buy
556
+525
+1,694% +$196K ﹤0.01% 2372
2019
Q2 		$15K Buy
+31
New +$21.9K ﹤0.01% 2435
2018
Q3 		– Sell
-1,037
Closed -$953K – 2380
2018
Q2 		$953K Buy
1,037
+1,033
+25,825% +$1.11M 0.01% 1294
2018
Q1 		$4K Buy
+4
New +$3.65K ﹤0.01% 2180
2015
Q4 		– Sell
-1,005
Closed -$790K – 2269
2015
Q3 		$790K Buy
+1,005
New +$1.23M ﹤0.01% 1311

Other funds holding ATRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jefferies Group's ATRA Position: Q3 2022 in Review

Jefferies Group sold out of Atara Biotherapeutics (ATRA) in Q3 2022, closing a stake of 2,800 shares — an estimated $545K sold.

Jefferies Group first reported a position in ATRA in Q3 2015 and held it in 7 quarters. The position peaked at $953K in Q2 2018. 154 funds tracked by Wall St. Rank hold ATRA as of Q3 2022.

  • Jefferies Group reported no remaining Atara Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Jefferies Group sold 2,800 Atara Biotherapeutics shares in Q3 2022, an estimated $545K.
  • Jefferies Group first reported a position in Atara Biotherapeutics in Q3 2015 and held it in 7 quarters.
  • Jefferies Group's Atara Biotherapeutics position peaked at $953K in Q2 2018.
  • 154 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.